Zevra Therapeutics, Inc.
ZVRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $24 | $27 | $10 | $29 |
| % Growth | -14% | 170.3% | -64.5% | – |
| Cost of Goods Sold | $7 | $3 | $0 | $2 |
| Gross Profit | $16 | $25 | $10 | $27 |
| % Margin | 68.6% | 89.3% | 97.8% | 92.8% |
| R&D Expenses | $42 | $40 | $20 | $10 |
| G&A Expenses | $0 | $0 | $15 | $9 |
| SG&A Expenses | $55 | $35 | $15 | $9 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | $0 |
| Other Operating Expenses | $6 | -$1 | $18 | $0 |
| Operating Expenses | $103 | $74 | $53 | $19 |
| Operating Income | -$87 | -$50 | -$43 | $8 |
| % Margin | -368.5% | -180.6% | -418.9% | 27% |
| Other Income/Exp. Net | -$3 | $4 | $16 | -$16 |
| Pre-Tax Income | -$90 | -$46 | -$27 | -$9 |
| Tax Expense | $15 | $0 | -$0 | $0 |
| Net Income | -$106 | -$46 | -$27 | -$9 |
| % Margin | -446.9% | -167.7% | -263.5% | -29.9% |
| EPS | -2.28 | -1.3 | -0.78 | -2.11 |
| % Growth | -75.4% | -66.7% | 63% | – |
| EPS Diluted | -2.28 | -1.3 | -0.78 | -2.11 |
| Weighted Avg Shares Out | 46 | 35 | 34 | 30 |
| Weighted Avg Shares Out Dil | 46 | 35 | 34 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $5 | $2 | $0 |
| Interest Expense | $7 | $2 | $0 | $0 |
| Depreciation & Amortization | $6 | $1 | $1 | $0 |
| EBITDA | -$76 | -$44 | -$26 | -$8 |
| % Margin | -323.6% | -158.6% | -251.2% | -27.5% |